"We previously filed applications for marketing approval of BELVIQ with the regulatory authorities for the European Union and Switzerland, and these regulatory authorities notified us that we had not yet satisfactorily addressed their concerns and that our applications would not be approved. We expect to continue to work with Eisai in pursuing regulatory approvals for BELVIQ in Europe and other territories outside the United States."
Hey, wait a second! The Q4 CC was on 2/27, 10-K out on 3/2 - that's only two days between the two events! ARNA HAD to have known about the Swissmedic rejection prior to the CC but refused to issue an 8-K as required or disclose it during the CC - BS! And I'll bet if I were to take the time to listen to the CC I'd hear something like "negotiations are ongoing", whereas in reality it was already a done deal - another SEC violation!
Thanks for posting this - I had completely forgotten where I heard it originally.
Not sure I mentioned this, but a young lady with whom I work (diabetic) was prescribed BELVIQ by her endocrinologist. He raved about the early results in his patients. Sadly, no insurance coverage from our provider, so the coast (this was a few months ago) was $350 monthly. She didn't want to pay - but told me he was very strong on it!
Somewhere here this will get a second big boost..just going to take time.
Market Data 
Markets 
AI
